Janumet (metformin/sitagliptin) / Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 13 Diseases   1 Trial   1 Trial   373 News 


12»
  • ||||||||||  Janumet (metformin/sitagliptin) / Merck (MSD), Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
    Hyperglycemic DKA in Patient on Monotherapy with SGLT-2 Inhibitor (ENDOExpo) -  May 11, 2023 - Abstract #ENDO2023ENDO_188;    
    Monotherapy of SGLT-2 inhibitors appears to not only have a risk of euglycemic diabetic ketoacidosis but also a risk of hyperglycemic diabetic ketoacidosis in type 2 diabetics. In this case we presented a case of hyperglycemic diabetic ketoacidosis in a type 2 diabetic on therapy with dapagliflozin.
  • ||||||||||  Journal:  Drugs for type 2 diabetes. (Pubmed Central) -  Nov 18, 2022   
    Therefore, the new products are expected to provide efficacy and tolerability similar to those of the reference products in the treatment of patients with type 2 diabetes (T2D). No abstract available
  • ||||||||||  metformin / Generic mfg.
    Journal:  Metformin-based single pill drug combinations for type 2 diabetes in primary care England: A time trend analysis. (Pubmed Central) -  May 19, 2022   
    Overall, an increase in prescription items can be seen for metformin-based single pill drug combinations along with an increase in their costs in primary care in England between 2015 and 2020. There was a declining trend for the number of ADRs reported per million prescription items dispensed for metformin-containing single pill combinations, even though their prescription rate increased.
  • ||||||||||  Janumet (metformin/sitagliptin) / Merck (MSD)
    Resolution of Gastroparesis Symptoms With the Removal of a Dipeptidyl Peptidase-4 Inhibitor (Shoreline Exhibit Hall) -  Sep 8, 2021 - Abstract #ACG2021ACG_564;    
    We describe a patient who presented with gastroparesis in the setting of sitagliptin and Janumet...The patient followed up in a gastroenterology clinic where sitagliptin was switched to metformin in an effort to rule out medication induced gastroparesis...Diabetes. 2007;56(5):1475-1480.
  • ||||||||||  Janumet (metformin/sitagliptin) / Merck (MSD)
    [VIRTUAL] Suicidality and the Covid-19 Pandemic () -  May 2, 2021 - Abstract #APA2021APA_555;    
    Upon evaluation, she reported her usual state of health until one day before presentation when she started feeling overwhelmed and overrun by life and being frustrated with coronavirus quarantine and swallowed 20 pills of Janumet (Sitagliptin/ Metformin)...Discussion This case supports and adds to the evidence in literature with regards to pandemic related suicidality presentation in a patient with no past psychiatry history. While suicidality is a common feature of depression and other mental illness, it is also important to assess acute suicide risk in younger vulnerable individuals without a psychiatric history in the context of ongoing COVID 19 pandemic.
  • ||||||||||  Janumet (metformin/sitagliptin) / Merck (MSD)
    Trial completion date, Trial primary completion date:  Comparing the Effect of Sitagliptin/Metformin and Metformin in PCOS Patients (clinicaltrials.gov) -  Mar 21, 2021   
    P1/2,  N=80, Recruiting, 
    Chinese Clinical Trial Registry (ChiCTR1900021861). Trial completion date: Jan 2021 --> Jul 2021 | Trial primary completion date: Jan 2021 --> Jul 2021
  • ||||||||||  Janumet (metformin/sitagliptin) / Merck (MSD)
    Trial completion:  SSS: Study of Sulphonylurea Synergy With DPP4 Inhibitors (clinicaltrials.gov) -  Mar 4, 2021   
    P=N/A,  N=30, Completed, 
    Trial completion date: Jan 2021 --> Jul 2021 | Trial primary completion date: Jan 2021 --> Jul 2021 Active, not recruiting --> Completed
  • ||||||||||  Janumet (metformin/sitagliptin) / Merck (MSD)
    Enrollment closed, Trial primary completion date:  SSS: Study of Sulphonylurea Synergy With DPP4 Inhibitors (clinicaltrials.gov) -  Nov 2, 2020   
    P=N/A,  N=30, Active, not recruiting, 
    Further follow up can be done to ensure these patients received the benefit of the DSM intervention. Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2020 --> Dec 2020
  • ||||||||||  Janumet (metformin/sitagliptin) / Merck (MSD)
    Trial completion date, Trial primary completion date:  Comparing the Effect of Sitagliptin/Metformin and Metformin in PCOS Patients (clinicaltrials.gov) -  Oct 22, 2020   
    P1/2,  N=80, Recruiting, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2020 --> Dec 2020 Trial completion date: May 2020 --> Jan 2021 | Trial primary completion date: May 2020 --> Jan 2021
  • ||||||||||  Janumet (metformin + sitagliptin) / Merck (MSD), glimepiride / Generic mfg., Invokana (canagliflozin) / J&J, Daiichi Sankyo, Mitsubishi Tanabe
    [VIRTUAL] Euglycemic Diabetic Ketoacidosis in a Patient on Canagliflozin Presenting With Hypoglycemia () -  Jun 20, 2020 - Abstract #ENDOI2020ENDO-I_1103;    
    Her past medical history is significant for type 2 Diabetes Mellitus, being managed on Canagliflozin, Glimepiride and Janumet. Our case highlights the importance of being vigilant in a patient on Canagliflozin, euglycemic DKA can occur even if they present initially with hypoglycemia and no acidosis.
  • ||||||||||  Janumet (metformin + sitagliptin) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS
    [VIRTUAL] A Case of Opdivo Induced Type 1 Diabetes () -  Jun 20, 2020 - Abstract #ENDOI2020ENDO-I_908;    
    At discharge she was continued on 22 units of levemir, a humalog sliding scale, and Janumet...Yervoy also carries a risk of further endocrine disorders, including increased risk of hypophysitis...It was crucial in this patient to identify this side effect of Opdivo, as it helped to prevent further episodes of DKA. Careful review of recent medication changes helped identify this uncommon complication of Opdivo and prompted a timely change in her diabetes care regimen.
  • ||||||||||  Janumet (metformin + sitagliptin) / Merck (MSD), glimepiride / Generic mfg., Invokana (canagliflozin) / J&J, Daiichi Sankyo, Mitsubishi Tanabe
    Euglycemic Diabetic Ketoacidosis in a Patient on Canagliflozin Presenting With Hypoglycemia (ENDOExpo) -  Apr 1, 2020 - Abstract #ENDO2020ENDO_4260;    
    Her past medical history is significant for type 2 Diabetes Mellitus, being managed on Canagliflozin, Glimepiride and Janumet. Our case highlights the importance of being vigilant in a patient on Canagliflozin, euglycemic DKA can occur even if they present initially with hypoglycemia and no acidosis.
  • ||||||||||  Janumet (metformin + sitagliptin) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS
    A Case of Opdivo Induced Type 1 Diabetes (ENDOExpo) -  Feb 7, 2020 - Abstract #ENDO2020ENDO_1935;    
    At discharge she was continued on 22 units of levemir, a humalog sliding scale, and Janumet...Yervoy also carries a risk of further endocrine disorders, including increased risk of hypophysitis...It was crucial in this patient to identify this side effect of Opdivo, as it helped to prevent further episodes of DKA. Careful review of recent medication changes helped identify this uncommon complication of Opdivo and prompted a timely change in her diabetes care regimen.
  • ||||||||||  Review, Journal:  Drugs for type 2 diabetes. (Pubmed Central) -  Dec 22, 2019   
    Careful review of recent medication changes helped identify this uncommon complication of Opdivo and prompted a timely change in her diabetes care regimen. No abstract available
  • ||||||||||  Janumet (metformin/sitagliptin) / Merck (MSD)
    Enrollment open, Trial primary completion date:  Metformin and Sitagliptin in Women With Previous Gestational Diabetes (clinicaltrials.gov) -  Jan 17, 2018   
    P2,  N=45, Recruiting, 
    Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2012 --> Dec 2018
  • ||||||||||  Janumet (metformin/sitagliptin) / Merck (MSD)
    Enrollment closed, Trial primary completion date, Monotherapy:  Sitagliptin + Metformin Compared to Metformin Monotherapy and Placebo in Women With a Recent GDM (clinicaltrials.gov) -  Aug 31, 2017   
    P4,  N=36, Active, not recruiting, 
    Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2012 --> Dec 2018 Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2018 --> Sep 2017
  • ||||||||||  Journal:  Heart Failure Considerations of Antihyperglycemic Medications for Type 2 Diabetes. (Pubmed Central) -  May 1, 2017   
    Acarbose, the dipeptidyl-peptidase 4-inhibitor sitagliptin, the glucagon-like peptide 1-receptor agonist lixisenatide based on presently available CVOT results comprise reasonable additional options, as significant harm in terms of HF has been excluded for those drugs...Although no HF harm was seen in CVOTs for insulin or sulfonylureas, they should be used only with caution in patients with HF, given their established high risk for hypoglycemia and some uncertainties on their safety in patients with HF derived from epidemiological observations. Pioglitazone is contraindicated in patients with HF>New York Heart Association I, despite some benefits suggested by CVOT subanalyses.